Summary
The AI claims provided are primarily about brand/somatropin equivalence and pricing/market dynamics. The supplied FDA label excerpts do not contain support for any pricing-related claims, and none of the non-pricing claims (e.g., “marca de somatropina”) are addressed in the provided label text. Therefore, most statements are unsupported relative to the provided label.
Category Scores
Accurate Statements
Humatrope es una versión de marca de somatropina (hormona de crecimiento).
The provided label excerpts identify the active ingredient as somatropin (recombinant human growth hormone), but do not explicitly state that Humatrope is a brand version of somatropin.
Unsupported Statements
En muchos países existen alternativas biosimilares de somatropina cuando están autorizados y disponibles.
No information in the provided label excerpts addresses availability of biosimilars by country.
El precio final de Humatrope para el paciente depende del sistema de reembolso y la cobertura del seguro.
No information in the provided label excerpts addresses patient pricing, reimbursement, or insurance coverage.
El precio final de Humatrope para el paciente depende de políticas de sustitución en farmacia.
No information in the provided label excerpts addresses pharmacy substitution policies or their effect on price.
El precio de Humatrope suele variar según el país.
No information in the provided label excerpts addresses pricing variation by country.
El precio de Humatrope suele variar según el formato (presentaciones).
No information in the provided label excerpts addresses pricing variation by formulation/presentation.
El precio de Humatrope suele variar según la dosis prescrita.
No information in the provided label excerpts addresses pricing variation by prescribed dose.
El precio de Humatrope suele variar según si se compra en farmacia o se obtiene por un programa de cobertura.
No information in the provided label excerpts addresses differences in price by purchase channel/program.
El precio de Humatrope suele depender del costo por vial o pluma.
No information in the provided label excerpts addresses cost per vial/cartridge/pen or how it impacts price.
El precio de Humatrope suele depender del número de unidades necesarias al mes.
No information in the provided label excerpts addresses price dependence on monthly units.
El precio puede ser afectado por el estado regulatorio o de patentes, lo cual puede influir en la competencia y el precio en el tiempo.
No information in the provided label excerpts addresses regulatory status/patents as determinants of price over time.
Cuando cambian las condiciones de exclusividad (patentes u otros tipos de protección) o entran competidores o biosimilares, el mercado suele ajustar precios con más oferta.
No information in the provided label excerpts addresses market dynamics or how competitors/biosimilars affect HUMATROPE pricing.
Contradictions
Important Omissions
No boxed warnings/contraindications/dosing/administration/safety monitoring details were provided in the AI claims, despite several statements being outside what the provided FDA label excerpts cover (pricing/market/biosimilars).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The audited claims are informational about pricing/availability and do not directly assert dosing, contraindications, or specific safety actions. However, because they are unsupported by the provided label excerpts, the information could mislead users about cost determinants rather than provide label-based prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims (especially those about patient pricing, insurance/reimbursement, substitution, and market/patent dynamics) are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict statements to what the provided label excerpts cover (indications, dosing/administration instructions, contraindications, warnings/precautions, drug interactions, adverse reactions, and monitoring). Avoid pricing/market/biosimilar availability claims unless the FDA label excerpt explicitly addresses them.